Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277322 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
A Phase 1 study, sponsored by Dan Feng.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07277322 is a Phase 1 study that has not yet begun recruiting, run by Dan Feng. The registered enrollment target is 24 participants.
The verdict
NCT07277322, a Phase 1 study, has not yet begun recruiting, sponsored by Dan Feng.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.
Interventions
- DRUG Dupilumab
- DRUG Toripalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07277322
The ClinicalTrials.gov registry entry for NCT07277322 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dan Feng, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dupilumab is the first listed.
NCT07277322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07277322 about?
NCT07277322 is a clinical study titled "Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases". This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.
What is the current status of trial NCT07277322?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-06-01. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT07277322?
The interventions under investigation include: Dupilumab (DRUG), Toripalimab (DRUG).
Who is sponsoring clinical trial NCT07277322?
This trial is sponsored by Dan Feng, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.